Articles tagged with Gene Therapy
Researchers at the University of Sheffield have developed a novel gene transfer system that can restore SMN protein levels and alleviate symptoms in SMA model mice. The new technique has the potential to develop a simple injection therapy without surgical interventions, offering significant implications for future SMA treatment.
A new gene therapy called SERCA2a has been shown to be safe and effective in reversing advanced heart failure by stimulating the production of an enzyme that enables the heart to pump more effectively. Patients who received SERCA2a demonstrated improvements in symptoms, heart function, and severity of heart failure.
Researchers at McGill University have discovered a way to control the normal expression of genes, including those active in cancer, through RNA interference. This breakthrough has important applications for laboratory research and could lead to the development of individually tailored cancer therapies.
Researchers found that increasing BMPR2 levels reduced pulmonary hypertension and strain on the heart in rat models of the disease. The study suggests that boosting BMPR2 levels could offer a new therapeutic target for treating PAH.
A consistent pattern in five genes has been found to predict the likelihood of relapse in pediatric T-cell acute lymphoblastic leukemia (T-ALL), allowing for more aggressive treatment to be administered from diagnosis. This discovery has significant potential to improve outcomes for patients at high risk of relapse.
A genetic link has been discovered between sporadic and familial forms of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. The study found that protein FUS forms characteristic inclusions in spinal motor neurons in most ALS cases, suggesting a common pathogenic pathway for motor neuron degeneration.
Veterinary scientists at Penn have successfully used a viral vector to target rod cells in the retina, a critical step towards developing gene therapies for inherited blindness. The study demonstrates the potential of this approach to correct diseases such as X-linked and autosomal dominant retinitis pigmentosa.
Researchers at Penn University successfully used gene therapy to restore retinal cone function and day vision in canines with inherited day blindness. The treatment was effective for younger dogs and held promise for future clinical trials.
A team of researchers from Université Laval has proven that it is possible to repair the defective gene responsible for Duchenne muscular dystrophy. They developed enzymes called meganucleases that can correct the dystrophin gene and restore its expression in muscle cells.
Researchers found that only patients with a specific genetic mutation are eligible for gene therapy, which has shown promising results in treating Leber congenital amaurosis. Genetic testing can detect changes in the genome, but accurate interpretation is crucial to ensure correct treatment.
An international expert group recommends individualized treatment for patients with type 2 diabetes, citing the need to address underlying physiological and genetic differences. The recommendations aim to improve glycemic control, minimize risk, and reduce diabetes complications by tailoring therapies to specific patient subgroups.
Scientists have successfully used gene therapy to restore vision in mice with retinitis pigmentosa, a degenerative eye disease. The treatment involved the use of compacted DNA nanoparticles, which improved structural and functional vision in affected mice, without any adverse effects.
The median survival time for metastatic breast cancer patients increased steadily over 25 years, with improved outcomes for those with grade III tumours. Targeted therapies, particularly trastuzumab, have contributed to these advancements, offering new hope for patients with aggressive forms of the disease.
Researchers at Cedars-Sinai Medical Center have identified over 30 regions of the genome linked to ulcerative colitis, providing insights into the disease's causes and potential new therapies. This understanding may lead to more effective treatments tailored to individual patients' needs.
A new gene therapy approach has shown promising results in treating spinal muscular atrophy (SMA) in mice by improving muscle strength, coordination, and locomotion. The treatment involves injecting the gene-carrying therapeutic directly into the brain and spinal cord of newborn mice.
Christopher Evans, a leading molecular biologist, has received the prestigious Arthur Steindler Award for his significant contributions to understanding musculoskeletal diseases. His innovative gene therapy work holds great promise as a new treatment option for managing rheumatoid arthritis and osteoarthritis.
Researchers at Universite de Montreal and VGTI have discovered a new mechanism by which HIV infects immune cells, characterizing the role of two molecules PD-1 and IL-10 in this process. The study suggests that blocking these interactions may restore the immune response in HIV-infected patients.
A second dose of gene therapy has proven safe and effective in animal studies, suggesting that patients who benefit from treatment in one eye may experience similar benefits in the other. The study found no signs of toxic side effects or interference from unwanted immune reactions.
Researchers used gene therapy to deliver a portion of DNA that makes the SMN protein into newborn mice, resulting in improved muscle coordination and longer survival. The treatment corrected motor function, restored nerve signals, and improved overall health in mice with spinal muscular atrophy.
Fetal surgery continues to evolve with advancements in prenatal diagnosis and surgical techniques. Experts at the Children's Hospital of Philadelphia describe innovative procedures for treating rare defects, including lung masses, sacrococcygeal teratomas, and spina bifida.
Physicist Alex Evilevitch directly measured the energy associated with viral DNA expulsion, a discovery that could lead to broad-spectrum antiviral drugs. The study used isothermal titration calorimetry and found that increasing DNA length increases heat release, highlighting the importance of hydration entropy in viral genome packaging.
A new study by the University of Pennsylvania School of Medicine found that extended use of a nicotine patch improves abstinence from cigarettes and helps smokers quit again after relapse. The extended therapy regimen was more effective in boosting abstinence rates than standard therapy.
A new tool called PEG-POD significantly increases gene delivery to retinal cells, outperforming existing carriers and DNA alone. This breakthrough may help develop therapies for conditions like retinitis pigmentosa and age-related macular degeneration.
University of Florida researchers are developing a gene therapy to treat Pompe disease, which causes severe muscle weakness and breathing difficulties. The treatment involves delivering a corrective gene directly to the diaphragm using an adeno-associated virus, with clinical trials expected to begin soon.
Researchers have achieved a breakthrough in regulating genes by hijacking riboswitches, opening doors for targeted drug discovery and synthetic biology. The study, published in Proceedings of the National Academy of Sciences, uses synthetic molecules to activate genes previously controlled by small naturally occurring molecules.
Researchers have identified a human genetic alteration associated with anxiety-related behavior in both humans and mice, which can inform the development of new clinical strategies to treat anxiety disorders. The study used functional magnetic resonance imaging (fMRI) to reveal altered brain function in individuals with this abnormality.
Researchers found that gene therapy to express a constitutively active form of protein I-1c in heart muscle cells improved contractile function in young mice, but led to abnormal heartbeats and sudden death under stress. Older mice developed characteristic features of heart failure after treatment.
Neuroscientists combined herpes and Sleeping Beauty to deliver larger genes to brain cells, increasing the size of genetic payload by nearly tripling it. This breakthrough technology could lead to treatments for devastating brain diseases like pediatric leukodystrophies and lysosomal storage disorders.
A study published in Cancer Cell reveals that epigenetic differences can distinguish patients with acute myeloid leukemia (AML) into subtypes with varying responsiveness to therapy. A set of 15-gene DNA methylation biomarkers was found to be highly predictive of patient survival.
Researchers from Boston University School of Medicine have discovered a gene therapy that can prevent the progression of emphysema by delivering therapeutic genes to lung tissue. The treatment achieved sustained expression of human alpha-1 antitrypsin protein, improving lung compliance and alveolar size in mice with emphysema.
An international team of researchers has identified a gene associated with DFN2, a rare form of progressive deafness that primarily affects males. The discovery offers therapeutic implications and may lead to treatments for other types of deafness.
Researchers at German Cancer Research Center find that HIV virus rarely integrates into genes with high transcription activity. This discovery could lead to the development of specific AIDS drugs targeting these 'cold spots', potentially offering a new approach to combat the virus.
Researchers identified specific genetic changes associated with an increased risk of relapse in cervical cancer patients. These changes are crucial steps in the progression of the disease towards an aggressive and treatment-resistant state.
Researchers have successfully transplanted genetically modified hematopoietic stem cells into mice, allowing their developing red blood cells to produce a critical lysosomal enzyme and preventing or reducing organ and central nervous system damage from Hurler's syndrome. This approach has the potential to improve treatment options for ...
Gene therapy has been successfully tested in France, halting the progression of adrenoleukodystrophy in two children. The innovative approach uses a modified HIV virus to deliver a therapeutic gene to bone marrow cells, which then migrate to the brain and display correcting potential.
Researchers have achieved significant success with gene therapy in treating adrenoleukodystrophy (ALD), a potentially fatal brain disorder. The treatment has arrested the progression of the disease in two boys, showing no adverse effects to date.
Researchers have successfully used a gene therapy technique to slow the onset of X-linked adrenoleukodystrophy, a severe brain disease, in two patients. The treatment involved introducing a therapeutic gene into blood cells using a lentiviral vector, which showed promise in slowing disease progression and improving neurological function.
Researchers successfully used gene therapy to repair injured human donor lungs, making them suitable for transplantation. The technique improves lung function and reduces inflammation, offering a promising approach to increase organ availability and improve patient outcomes.
A gene therapy treatment has successfully restored vision in five children and seven adults with Leber's congenital amaurosis, a group of inherited blinding diseases. The treatment uses genes to produce light-sensitive pigments in the back of the eye, allowing patients to navigate low-light environments and perform daily activities.
Gene therapy has been shown to improve vision in children with Leber congenital amaurosis, a severe form of inherited retinal degeneration. The treatment resulted in significant improvements in both subjective and objective measurements of vision.
Researchers determine the three-dimensional structure of Pur-alpha protein, essential for normal neural function, and gain insights into its molecular function. The findings provide a possible basis for developing an effective therapy for Fragile X tremor/ataxia syndrome.
A new publication in Molecular Therapy outlines the dramatic effects of an exon skipping PPMO in preventing severe deterioration of dystrophin-deficient mice. The treatment restores dystrophin protein expression and maintains near-normal muscle function, suggesting great potential for treating Duchenne muscular dystrophy patients.
Researchers have tested various cell-based therapies in mice with Alport syndrome, a genetic kidney disease. Stem cell treatments may repair kidney defects associated with the disease, offering promise for patients.
Researchers have identified a genetic factor that increases the risk of sudden cardiac death in patients with congenital long-QT syndrome. Variants of the gene NOS1AP were found to predispose individuals to a worse form of the disease, leading to longer QT intervals and increased symptoms.
Cold Spring Harbor Laboratory scientists uncover a large cache of genes that act as built-in barriers against cancer, including over 10 new tumor suppressor genes. The study reveals that even partial loss of function in these genes can accelerate tumor growth.
Parkinson's Disease (PD) incidence increases with age, with a wide variation in onset age ranging from 20 to 90 years. Researchers have identified genes influencing PD onset age, which may help identify mechanisms and therapeutic targets for delaying symptoms.
Scientists used gene transfer to increase heart muscle cell contractions, improving cardiac function and quality of life for patients. The fast molecular motor gene transfer showed promise in reversing the course of heart failure.
Scientists at the University of York have successfully silenced a gene that appears essential to cancer cell survival, leaving healthy cells unaffected. This discovery suggests that certain genes may be specific to cancer cells, paving the way for the development of new cancer treatments with fewer side effects.
Researchers have discovered 231 new genes linked to head and neck cancer, which could aid in early detection and treatment. These findings may also help monitor disease progression and patient response to therapy.
Van Andel Institute researchers found the gene RhoB is crucial in the progression of Myelodysplastic Syndrome (MDS), a bone marrow disease affecting up to 15,000 people annually. The study's findings may lead to new treatments for late-stage MDS and its potential applications in leukemia and solid tumors.
Researchers are conducting a phase II gene therapy trial using CERE-110 to treat patients with mild Alzheimer's disease. The study aims to determine the safety and benefits of injecting the gene into the brain, which produces Nerve Growth Factor to help nerve cells survive.
Researchers have uncovered the genetic switch that controls macrophage polarization, essential for muscles to regenerate properly. Macrophage polarization allows them to shift from clearing debris to promoting repair in damaged areas.
Researchers at the University of Edinburgh have identified a protein that enables sections of so-called junk DNA to be cut and pasted within genetic code. This finding could speed up the development of gene therapies by allowing scientists to control the process of DNA transposition.
Researchers have found a genetic link between inherited cardiac arrhythmias and thyroid dysfunction, suggesting that mutations in the KCNE2 and KCNQ1 genes could also cause thyroid problems. The study's findings may lead to new treatments for both heart and endocrine diseases.
Researchers from the University of Florida and the University of Washington successfully used gene therapy to restore color vision in two squirrel monkeys. The study demonstrates the potential for this treatment to target adult vision disorders involving cone cells, a crucial step towards developing therapies for human cone diseases.
A Mayo Clinic study has found two genes associated with good central nervous system repair in mice with multiple sclerosis. The identification of these genes may lead to the development of new therapies and a better prediction of patient outcomes.
A new tumor marker has been identified for brain tumor resistance, allowing for targeted therapy approaches. The discovery of a
GS-101 demonstrates significant inhibition and regression of corneal neovascularisation in a phase II study. The treatment is generally well-tolerated with no serious side effects, offering a new approach to managing ophthalmic angiogenesis.
The PREDICT score identifies individual risk for poor responsiveness to clopidogrel through non-genetic factors. Studies show that response to clopidogrel is affected by genetic variants involving enzymes responsible for absorption and bio-activation of the medication.
Researchers created a new gene therapy vector that uses the same machinery as viruses to deliver therapeutic genes into cells' nuclei. This breakthrough improves efficiency and specificity of human gene therapy, paving the way for clinical applications.